Share on LinkedInShare on LinkedIn

ARTICLE · 24 FEBRUARY 2024

Navigating The Pending BIOSECURE Act: Implications For U.S.-China Biopharmaceutical Collaboration And National Security

Arnold & Porter
Arnold & Porter
Contributor
Arnold & Porter

Arnold & Porter

With over 1,000 lawyers across 16 offices worldwide, Arnold & Porter is renowned for its...

View firm profile
Explore more from Arnold & Porter

The BIOSECURE Act (H.R. 7085), which has the potential to severely restrict the ability of U.S. biopharmaceutical companies to collaborate with certain Chinese entities without losing the ability to contract with the U.S. government, has made headlines in recent weeks.

United StatesTechnology

The BIOSECURE Act (H.R. 7085), which has the potential to severely restrict the ability of U.S. biopharmaceutical companies to collaborate with certain Chinese entities without losing the ability to contract with the U.S. government, has made headlines in recent weeks.

As we have seen previously in the telecommunications field, congressional scrutiny of Chinese companies such as BGI Genomics, MGI, Complete Genomics, and WuXi AppTec has been building over the past several years as federal policymakers have become increasingly critical of China's biopharmaceutical industry, with a focus on their alleged ties to the Chinese Communist Party and handling of Americans' personal data, including genetic information. Introduced by the House Select Committee on the Chinese Communist Party (China Select Committee) Chairman Mike Gallagher (R-WI) and Ranking Member Raja Krishnamoorthi (D-IL) on January 25, the BIOSECURE Act would:

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from